Likewise, for glutaminase inhibitor bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)-ethyl-sulfide (BPTES), and PDK inhibitor dichloroacetate (DCA) a dose-dependent reduction in residual viability was observed in all three groups being significantly affected in PAH-EC (Fig. 5B,C) Mitochondrial pyruvate carrier blocker 2-Cyano-3-(1-phenyl-1H-indol-3-yl)-2-propenoic-acid (UK-5099) showed a significant dose-dependent reduction in viability in all three groups but no difference was found in viability among groups (Fig. 5D). Here, GLS is linked to pulmonary arterial hypertension.